聯環藥業(600513.SH):2024年淨利潤8416萬元,同比下降37.66%
格隆匯4月17日丨聯環藥業(600513.SH)公佈2024年年度報告,2024年公司全年實現營業收入21.6億元,同比下降0.63%;實現歸母淨利潤8416萬元,同比下降37.66%;基本每股收益0.29元。擬向全體股東每10股派發現金紅利0.89元(含稅)。公司本期歸母淨利潤下降37.66%,主要由於研發投入大幅增長,此外,部分子公司研發投入較多,較上年投資收益減少。同時受醫保政策、市場需求變化和市場結構調整等綜合因素影響,期間費用上漲,主要系人工薪酬以及市場服務費增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.